tailieunhanh - S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial

This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer. Methods: Patients received AC every 3 weeks for four cycles followed by S-1 (30 mg/m2 orally . on days 1–14) and docetaxel (75 mg/m2 . on day 1) every 3 weeks for four cycles. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN